(from my presentation at #DData19 regarding what we're learning in the real world with DIYAPS systems like #OpenAPS.)
First, some context - it was 5 years ago at one of the early DData meetings that @scottleibrand & I shared about the smart, louder alarm system (#DIYPS) that we had created & I had used in the last year...and what we planned to do next, like trying to close the loop. #DData19
And we did! We closed the loop for me in Dec. 2014, and launched #OpenAPS in February 2015.
Why was it worth doing? Automated insulin delivery has so many benefits compared to old-school "manual" diabetes. #DData19
But one early piece of push-back we got was: "well, it clearly works for you, but how do you know it works for anyone else?"
We didn't, but we felt it was important to share design (openaps.org/reference-desi…) & code & let others build from it & learn from what we learned. #DData19
To help answer the question if it worked for other people, though, we did a survey of the early adopters in the community and presented it at ADA Scientific Sessions in 2016, and also followed up with a publication about it in a journal. #DData19
And in the last 5 years, we now know that there's not just one, not just a few, but many thousands of people globally using DIYAPS systems.
And here's what we've learned in the real-world community as a result:
There's oodles of research now published in the literature & being presented at scientific conferences. They all generally have the same results; A1c goes down, TIR goes up, time spent hypo and hyper goes down. #DData19
And, there have not just been retrospective real-world data studies, there have also been observational studies, prospective studies (including this one at EASD: bit.ly/2NVfOmC), and there are RCTs of DIYAPS in the works. #DData19
2. We also are learning *why* people are choosing to DIYAPS.
The @OPENDiabetesEU project (of which I am a part) did a survey last year called "DIWHY". This survey also showed TIR & A1c improvements, as well as revealed many of the reasons why people are using DIY. #DData19
3. DIYAPS may use "simple" algorithms, but they're effective. "Machine learning"/"AI" is not required to get best-in-world results.
For example - with slightly faster (~45min peak time) insulin and algorithm improvements in DIYAPS, I no longer have to bolus for meals. #DData19
So no matter what life throws my way - like my nephew giving me + 16 other people norovirus a few years ago at Thanksgiving, where I didn't eat for 3 days 🤢, or falling off a mountain and breaking my ankle in 3 places - I do less work, and get fantastic results. #DData19
4. We also know we can quantify different diabetes behaviors, and separate the impact of these behaviors.
For example: what is the difference for A1c + TIR in someone who stops meal bolusing and announcing meals? Or mostly announces but doesn't bolus? etc. #DData19
5. And we now have data & capability to answer questions we never thought possible for individuals...like understanding when pump sites become ineffective on average; where does someone get the best accuracy based on CGM body placement; best methods for exercise; etc. #DData19
6. But there's still a LOT of low-hanging fruit left to improve QOL for PWD. It's not enough to have these capabilities if we don't use them. This is a call to action for you, industry: do more. Do better. Go faster. We can do more to improve QOL for PWD. #DData19
For example, a lot of researchers think they've reached the frontier, the bleeding edge, and are studying DIY (something). However..... we're over here. We haven't stopped in the last 5 years. #DData19
I recognize, though, researchers typically study the way the world 'is'. But we patients are designing our future, the future we need diabetes care to be, the way things 'ought' to be. And that's sometimes why there is a gap. #DData19
We ought to have real-time access to all our data (all device types) on the device of our choosing. We ought to have reliable, accurate, affordable, and accessible devices, too. #DData19
We ought to have interoperability in all of these devices; and we ought to have the flexibility to do *less* work and achieve *better* outcomes. We also should be able to define our priorities, for our real lives, rather than these being defined by industry. #DData19
So at the end of the day - we are (still) not waiting. We've all (in the DIY and diabetes communities, and industry), made progress. But it's not enough. We can, and should, do more. Please join us. #WeAreNotWaiting
1/ What if there was a tool to help identify who might have exocrine pancreatic insufficiency (EPI/PEI)?
EPI is a significant issue for many people with diabetes (likely more common than gastroparesis or celiac).
Here's how such a tool can help PWD👇🏼🧵
#ADASciSessions #ADA2024
2/ The Exocrine Pancreatic Insufficiency Symptom Score (EPI/PEI-SS) has 15 symptoms, rated by how frequent they are and how bothersome they are (aka severity).
n=324 ppl participated in a real-world survey.
n=118 were people with diabetes (PWD)!
#ADASciSessions #ADA2024
3/ Methods:
EPI/PEI-SS scores were analyzed and compared between PWD (n=118), with EPI (T1D: n=14; T2D: n=20) or without EPI (T1D: n=78; T2D: n=6), and people without diabetes (n=206) with and without EPI.
📣 Presentation of the primary outcome results from the CREATE Trial, which assessed open source automated insulin delivery (AID) compared to sensor-augmented pump therapy (SAPT) in adults & kids with T1D, at #ADA2022!
The CREATE trial aimed to study the efficacy and safety of an open source automated insulin delivery system, with a large scale, long term randomized controlled trial.
I just realized it's been 3 (!) years since I published my book on automated insulin delivery, with the goal of helping increased conversation and understanding of AID technology for people with diabetes, their loved ones, and healthcare providers!
I'm still very proud that it is available to read for free online, free to download a PDF (both of which have been done thousands of times each: ArtificialPancreasBook.com), or as an e-book, paperback, and now hardback copy. Proceeds from the purchased copies go to Life For A Child.
And, more recently, it has also been translated into French by the wonderful Dr. Mihaela Muresan and Olivier Legendre!
The French translation is available in Kindle, paperback, hardback, or free PDF download formats as well.
1/THREAD - my presentation is kicking off at #EASD2020 about open source automated insulin delivery.
(You can see a full version of my presentation here: bit.ly/DanaMLewisEASD…, or read the summary below!)
Note we should differentiate between open source (where the source of something is open), and DIY (do-it-yourself) implementations of open source code. Open source means it can be reviewed and used by individuals (thus, DIY or #DIYAPS) or by companies.
Poster 988-P at #ADA2020 by Jennifer Zabinsky, Haley Howell, Alireza Ghezavati, @DanaMLewis Andrew Nguyen, and Jenise Wong: “Do-It-Yourself Artificial Pancreas Systems Reduce Hyperglycemia Without Increasing Hypoglycemia”
This was a retrospective double cohort study that evaluated data from the @OpenAPS Data Commons (data ranged from 2017-2019) and compared it to conventional sensor-augmented pump (SAP) therapy from the @Tidepool_org Big Data Donation Project. #ADA2020
One month of CGM data (with more than 70% of the month spent using CGM), as long as they were >1 year of living with T1D, was used from the @OpenAPS Data Commons. People could be using any type of DIYAPS (OpenAPS, Loop, or AndroidAPS) and there were no age restrictions. #ADA2020
Poster 99-LB at #ADA2020 by @danamlewis, @azure_dominique, and Lance Kriegsfeld, “Multi-Timescale Interactions of Glucose and Insulin in Type 1 Diabetes Reveal Benefits of Hybrid Closed Loop Systems“
Background - Blood glucose and insulin exhibit coupled biological rhythms at multiple timescales, including hours (ultradian, UR) and the day (circadian, CR) in individuals without diabetes. But, biological rhythms in longitudinal data have not been mapped in T1D. #ADA2020
It is not known exactly how glucose and insulin rhythms compare between T1D and non-T1D, and whether rhythms are affected by type of therapy (Sensor Augmented Pump (SAP) or Hybrid Closed Loop (HCL)). #ADA2020